Humana Inc.
HUM · NYSE
Analyst Consensus
Hold
Analyst Ratings Synthesis
Consensus is Hold from 20 analysts, with a mean price target of $415. The supplied consensus does not report low or high targets, so target dispersion and the width of the range cannot be measured. No named analyst or firm is identified as most or least bullish, and the evidence supplies no rating or target revisions during the week. The substantive disagreement behind any target spread is therefore not documented. Fundamentally, the available research tension is between management’s stated 2027 Medicare Advantage margin-expansion and Stars-progress plan and the absence of quantified execution evidence in the supplied material.
Rating Actions
No individual rating actions have been captured for HUMyet. Consensus figures above come from Nasdaq's aggregate feed.
